Wat wij financieren (alleen in het Engels)

Funded projects
1,250+
Men's Health Partners
20
Countries
20
We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact.
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“The number of men taking their own lives around the world is one of the biggest challenges of our time. Movember is working to ensure all men and boys look after their mental health and are comfortable to seek help when they’re struggling.”
Brendan Maher, Global Director, Mental Health and Suicide Prevention.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

GAP6 - Oligometastatic prostate cancer

Movember Funding to Date

EUR 7,015

What we seek to achieve

To identify those prostate cancer patients in an intermediate stage of cancer spread who will benefit from radical treatment of their primary tumour and metastases based on shared biological characteristics.

Country
Switzerland
Implemented by
Movember Foundation
Project start date
Jan 2018
Project Status
In Progress

About the project

In 2016, sixteen groups from institutions around the globe were selected to pool samples and knowledge on prostate cancer with intermediate spread. Bone and blood tissue samples as well as clinical information will be collected from patients enrolled in clinical trials of metastatic prostate cancer or having samples taken for diagnosis and shared internationally. Samples will be analysed collectively by the group for insights that cannot be gained from the smaller sample numbers available to each group.

Cancer cells in general undergo major changes in long-term data storage (genes) and how this is translated to the protein level (gene transcription). This project will study whether specific changes in genes or their transcription can be linked to improved survival after radical treatment of low-spread cancer.

Discovering biological markers that identify intermediate spread patients who would benefit from radical therapy would have a huge impact on treatment management. Patients unlikely to experience benefits from the treatment would be spared treatment costs and side effects as well as being directed towards other more promising treatments.

>
Page 1 of 29